Development of in vitro procedures that can better predict the safety of therapeutic monoclonal antibodies
Pre-clinical safety testing (in vivo and in vitro) of the therapeutic monoclonal antibody (mAb) TGN1412 (developed for the treatment of autoimmune diseases) failed to predict the life threatening adverse events that occurred during its Phase I Clinical Trial. The treatment of disease using mAb thera...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2012
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.565728 |